Millions of patients undergoing esketamine treatment spend their mandatory two-hour post-dose observation in sterile isolation, letting a critical surge of neuroplasticity simply evaporate. A groundbreaking clinical manual published in Psychedelics challenges this passive waiting room model by pairing intranasal esketamine with Acceptance and Commitment Therapy (ACT) during the acute drug window.This protocol targets the post-peak 60-minute window, using heightened sensory awareness to ground patients and cognitive defusion to dismantle rigid depressive narratives. By pairing drug-induced openness with values-based action, the model aims to foster enduring psychological flexibility rather than temporary relief. Tune in to explore how transforming a passive clinical safety check into an active therapeutic workshop could revolutionize depression treatment.Resources:Mathai, D. S., Pilecki, B., Zaki, H., Morris, T., Morris, M., & Garcia-Romeu, A. (2026). Esketamine and Acceptance and Commitment Therapy (ACT) for treatment-resistant depression: An intervention-development framework and treatment manual. Psychedelics, 100046. https://doi.org/10.1016/j.psyche.2026.100046